+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Eating Disorders

  • ID: 4533534
  • Report
  • 42 Pages
  • Datamonitor Healthcare
1 of 3

FEATURED COMPANIES

  • Edgemont
  • Eli Lilly
  • Takeda
  • MORE
This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • Worldwide, the author estimates that in 2017, there were approximately 35.6 million prevalent cases of eating disorders in females aged 10–19 years, including 3.0 million cases of anorexia nervosa, 11.6 million cases of bulimia nervosa, and 14.3 million cases of binge eating disorder.
  • In this demographic group, the author forecasts the number of prevalent cases of eating disorders to increase to 38.1 million by 2026.
  • Edgemont’s fluoxetine tablets, Eli Lilly’s Prozac, and Takeda’s Vyvanse are the only FDA-approved drugs for eating disorders. These drugs are administered via the oral route, with Vyvanse also available in an intranasal formulation.
  • There are only two industry-sponsored drugs in active clinical development for eating disorders, with one drug each in Phase II and the NDA/BLA Phase.
  • Therapies in mid-to-late-stage development for eating disorders focus on targets such as dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, and ghrelin receptor. These drugs are administered via the oral and subcutaneous routes.
  • The only high-impact upcoming event in the eating disorders space is an expected PDUFA date for dasotraline. The overall likelihood of approval of a Phase I psychiatry-other asset is 11.3%, and the average probability a drug advances from Phase III is 78.6%. Drugs, on average, take 9.1 years from Phase I to approval, compared to 8.8 years in the overall psychiatry space.
  • There have been only three licensing and asset acquisition deals involving eating disorders drugs during 2014–19. The values were not disclosed for any of these deals.
  • The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for eating disorders have been in the late phase of development, with 91% of trials in Phase III, and only 9% in Phase II.
  • The US leads in terms of the number of eating disorders clinical trials globally, while Germany leads the major EU markets. Clinical trial activity in the eating disorders space consists entirely of completed trials. Takeda has the highest number of completed clinical trials for eating disorders, with four trials.
  • Takeda leads industry sponsors with the highest overall number of clinical trials for eating disorders.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Edgemont
  • Eli Lilly
  • Takeda
  • MORE
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
  • Subtypes
TREATMENT
  • Psychotherapy
  • Medications
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • Relamorelin for Eating Disorders (June 25, 2019)
  • OPNT001 for Eating Disorders (February 21, 2019)
  • Dasotraline for Eating Disorders (July 25, 2018)
KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
BIBLIOGRAPHY
  • Prescription information
APPENDIX

LIST OF FIGURES
Figure 1: Trends in worldwide prevalent cases of eating disorders in females aged 10–19 years, 2017–26
Figure 2: Overview of pipeline drugs for eating disorders in the US
Figure 3: Pipeline drugs for eating disorders, by company
Figure 4: Pipeline drugs for eating disorders, by drug type
Figure 5: Pipeline drugs for eating disorders, by classification
Figure 6: OPNT001 for Eating Disorders (February 21, 2019): Phase II - Bulimia Nervosa (U.K.)
Figure 7: Dasotraline for Eating Disorders (July 25, 2018): Phase III - SEP360-321
Figure 8: Key upcoming events in eating disorders
Figure 9: Probability of success in the eating disorders pipeline
Figure 10: Licensing and asset acquisition deals in eating disorders, 2014–19
Figure 11: Clinical trials in eating disorders
Figure 12: Top 10 drugs for clinical trials in eating disorders
Figure 13: Top 10 companies for clinical trials in eating disorders
Figure 14: Trial locations in eating disorders
Figure 15: Eating disorders trials status
Figure 16: Eating disorders trials sponsors, by phase

LIST OF TABLES
Table 1: Worldwide prevalent cases of eating disorders in females aged 10–19 years, 2017–26
Table 2: Prevalent cases of eating disorders in females aged 10–19 years in Africa, 2017–26
Table 3: Prevalent cases of eating disorders in females aged 10–19 years in Asia, 2017–26
Table 4: Prevalent cases of eating disorders in children aged 10–19 years in Latin America and the Caribbean, 2017–26
Table 5: Prevalent cases of eating disorders in children aged 10–19 years in Northern America, 2017–26
Table 6: Prevalent cases of eating disorders in children aged 10–19 years in Oceania, 2017–26
Table 7: Prevalent cases of eating disorders in all ages in Europe, 2017–26
Table 8: Marketed drugs for eating disorders
Table 9: Pipeline drugs for eating disorders in the US
Table 10: Relamorelin for Eating Disorders (June 25, 2019)
Table 11: OPNT001 for Eating Disorders (February 21, 2019)
Table 12: Dasotraline for Eating Disorders (July 25, 2018)
Table 13: Parent patents in eating disorders
Table 14: Historical global sales, by drug ($m), 2014–18
Table 15: Forecasted global sales, by drug ($m), 2019–23
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Edgemont
  • Eli Lilly
  • Takeda
Note: Product cover images may vary from those shown
Adroll
adroll